Login Join us
Benefits Strategy

New Entrants Create Price Competition and Drive New Formulary Solutions in Hepatitis C Market

The market for pharmaceutical therapies to treat chronic hepatitis C changed dramatically in late 2013, when a groundbreaking, curative medication, Sovaldi (Gilead Sciences), was granted approval from the U.S. Food and Drug Administration.

icon_featured_hand

January 09, 2020

More in Benefits Strategy

TABLE OF CONTENTS

  1. Setting the Stage
  2. Background Information
  3. New Treatments and Clinical Breakthroughs
  4. Declining Utilization and Exclusivity Deals Accelerate Innovation in Formulary Creation
  5. What Employers Can Do